# Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT03691714** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Trisha Wise-Draper** · enrollment: 36 (actual)

## Conditions studied

- Recurrent Head and Neck Cancer
- Head and Neck Cancer
- Head and Neck Neoplasms
- Metastatic Cancer

## Interventions

- **DRUG:** Durvalumab
- **DRUG:** Cetuximab

## Key facts

- **NCT ID:** NCT03691714
- **Lead sponsor:** Trisha Wise-Draper
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2018-10-23
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2023-12-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03691714

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03691714, "Durvalumab (MEDI4736) With Cetuximab in Previously Treated Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT03691714. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*